Accordingly, the WHO 2022 classification recognizes NPM1-mutated AML as a distinct entity, and the ELN 2022 risk stratification classifies patients with NPM1-mutated, FLT3-ITD-negative AML as favorable risk [3]. This evidence concerns the gene FLT3 and acute myeloid leukemia.